• Traws Pharma reported final Phase 2a results showing ratutrelvir delivered symptom resolution comparable to Paxlovid, with fewer treatment-related adverse events.
• No viral rebound occurred through follow-up; Paxlovid-ineligible patients receiving ratutrelvir had similar outcomes without treatment-related adverse events.
• Planned FDA discussions will focus on a registration pathway for high-risk adults ineligible for Paxlovid.
• Tivoxavir marboxil’s completed tablet bridging study supported potential once-monthly influenza prevention dosing; the formulation was well tolerated.
• Completed toxicology retesting supports a planned regulatory resubmission in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-125797), on November 12, 2026, and is solely responsible for the information contained therein.